IRB InvIT Fund 
Dealstreet

Trilegal, JSA act on IRB InvIT Fund ₹3,248.43 crore QIP

The proceeds of the QIP are to be used for part funding of consideration for acquisition of the Target SPVs from IRB Infrastructure Trust.

Bar & Bench

IRB InvIT Fund has made the the largest qualified institution's placement of units by an InvIT in YTD Fiscal 2026, aggregating to ₹3248.43 crore.

Trilegal has acted as legal counsel to IRB InvIT Fund and IRB Infrastructure Private Limited on this QIP.

The transaction team was led by Abhinav Maker (Partner), with support from Associates Mrinal Kumar, Kalyan Reddy, Varda Saxena and K. Prashant Agrawal and Trainee Associate Revant Gupta.

Abhinav Maker

JSA Advocates & Solicitors advised the lead managers Kotak Mahindra Capital Company Limited, CLSA India Private Limited and Motilal Oswal Investment Advisors Limited on this QIP.

The transaction team consisted of Arka Mookerjee (Lead Partner), Pracheta Bhattacharya (Partner), Sourav Modi (Principal Associate), Ananth Balaji (Principal Associate), and Associates Jeebitesh Bhattacharya, Bhavna Sancheti, Aditya Shendye, Palak Karundia and Ayushi Pandit.

Arka Mookerjee, Pracheta Bhattacharya

As of June 30, 2025, IRB InvIT Fund operated and maintained 2,421 lane kilometers across a portfolio of six operational projects which includes five (5) Build-Operate-Transfer road infrastructure assets and one (1) Hybrid Annuity Mode road infrastructure asset, across the high growth western and southern belt of India in the states of Punjab, Karnataka, Rajasthan, Tamil Nadu, Maharashtra, and Gujarat offering a mix of fixed and variable revenue-generating assets.

The proceeds of the QIP are to be used for part funding of consideration for acquisition of the Target SPVs from IRB Infrastructure Trust, including by way of shareholder loans to Target SPVs for repayment/prepayment, in full or part, of the outstanding subordinated debt and unsecured loans availed by the Target SPVs and other general corporate purposes.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Delhi High Court allows Sun Pharma to manufacture and export Ozempic-like drug, but no sale in India

Defending Champions LKS to face SAM in the Cup Division Final of 17th SILF Turf Cricket League

Khaitan & Co acts on JSW Steel - JFE Steel joint venture

Delhi High Court seeks Centre's response on plea to make TV content accessible for persons with disabilities

Thiruparankundram temple lamp row: Madras HC notices "pattern" in defying orders, summons State officials

SCROLL FOR NEXT